CANbridge Pharmaceuticals, Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development, and commercialization of transformative therapies, announced that it has entered into a research collaboration and license agreement with Scriptr Global, Inc., for the development of a gene therapy treatment targeting dystrophinopathies. CANbridge will gain exclusive worldwide rights to develop, manufacture, and commercialize a gene therapy candidate for the treatment of dystrophinopathies, using Scriptr Global’s Stitchr™ platform, a proprietary ribozyme-mediated RNA assembly technology. Scriptr Global will be responsible for research, while CANbridge will assume all responsibilities for development, manufacturing, regulatory, and commercialization.
The financial terms of the agreement include an upfront payment, development, and sales payments, upon hitting certain milestones, as well as royalties based on net sales.
“We are pleased to be aligning with Scriptr Global and the Stitchr technology platform, which we believe has the potential to revolutionize the dystrophinopathy gene therapy field,” said James Xue, Ph.D., Founder, Chairman, and CEO of CANbridge Pharmaceuticals, Inc.
“The need for a transformative therapeutic approach for those individuals and families impacted with dystrophinopathies is great. Scriptr Global is delighted to undertake this important work with CANbridge utilizing Scriptr Global’s novel platform technology,” stated Keith Alkek, Co-Founder Chairman and CEO of Scriptr Global, Inc.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace
